Cargando…

Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening

BACKGROUND: Schistosomiasis is a neglected tropical disease caused by trematodes of the genus Schistosoma, with a limited treatment, mainly based on the use of praziquantel (PZQ). Currently, several aspartic proteases genes have already been identified within the genome of Schistosoma species. At le...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Bárbara Figueira, Senger, Mario Roberto, Moreira-Filho, José Teófilo, de Vasconcellos, Fabio Jorge, Dantas, Rafael Ferreira, Owens, Raymond, Andrade, Carolina Horta, Neves, Bruno Junior, Silva-Junior, Floriano Paes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Oswaldo Cruz, Ministério da Saúde 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481938/
https://www.ncbi.nlm.nih.gov/pubmed/37672425
http://dx.doi.org/10.1590/0074-02760230031
_version_ 1785102084481220608
author Gomes, Bárbara Figueira
Senger, Mario Roberto
Moreira-Filho, José Teófilo
de Vasconcellos, Fabio Jorge
Dantas, Rafael Ferreira
Owens, Raymond
Andrade, Carolina Horta
Neves, Bruno Junior
Silva-Junior, Floriano Paes
author_facet Gomes, Bárbara Figueira
Senger, Mario Roberto
Moreira-Filho, José Teófilo
de Vasconcellos, Fabio Jorge
Dantas, Rafael Ferreira
Owens, Raymond
Andrade, Carolina Horta
Neves, Bruno Junior
Silva-Junior, Floriano Paes
author_sort Gomes, Bárbara Figueira
collection PubMed
description BACKGROUND: Schistosomiasis is a neglected tropical disease caused by trematodes of the genus Schistosoma, with a limited treatment, mainly based on the use of praziquantel (PZQ). Currently, several aspartic proteases genes have already been identified within the genome of Schistosoma species. At least one enzyme encoded from this gene family (SmAP), named SmCD1, has been validated for the development of schistosomicidal drugs, since it has a key role in haemoglobin digestion by worms. OBJECTIVE: In this work, we integrated a structure-based virtual screening campaign, enzymatic assays and adult worms ex vivo experiments aiming to discover the first classes of SmCD1 inhibitors. METHODS: Initially, the 3D-structures of SmCD1, SmCD2 and SmCD3 were generated using homology modelling approach. Using these models, we prioritised 50 compounds from 20,000 compounds from ChemBridge database for further testing in adult worm aqueous extract (AWAE) and recombinant SmCD1 using enzymatic assays. FINDINGS: Seven compounds were confirmed as hits and among them, two compounds representing new chemical scaffolds, named 5 and 19, had IC(50) values against SmCD1 close to 100 μM while presenting binding efficiency indexes comparable to or even higher than pepstatin, a classical tight-binding peptide inhibitor of aspartyl proteases. Upon activity comparison against mammalian enzymes, compound 50 was selective and the most potent against the AWAE aspartic protease activity (IC(50) = 77.7 μM). Combination of computational and experimental results indicate that compound 50 is a selective inhibitor of SmCD2. Compounds 5, 19 and 50 tested at low concentrations (10 uM) were neither cytotoxic against WSS-1 cells (48 h) nor could kill adult worms ex-vivo, although compounds 5 and 50 presented a slight decrease on female worms motility on late incubations times (48 or 72 h). MAIN CONCLUSION: Overall, the inhibitors identified in this work represent promising hits for further hit-to-lead optimisation.
format Online
Article
Text
id pubmed-10481938
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Instituto Oswaldo Cruz, Ministério da Saúde
record_format MEDLINE/PubMed
spelling pubmed-104819382023-09-07 Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening Gomes, Bárbara Figueira Senger, Mario Roberto Moreira-Filho, José Teófilo de Vasconcellos, Fabio Jorge Dantas, Rafael Ferreira Owens, Raymond Andrade, Carolina Horta Neves, Bruno Junior Silva-Junior, Floriano Paes Mem Inst Oswaldo Cruz Research Article BACKGROUND: Schistosomiasis is a neglected tropical disease caused by trematodes of the genus Schistosoma, with a limited treatment, mainly based on the use of praziquantel (PZQ). Currently, several aspartic proteases genes have already been identified within the genome of Schistosoma species. At least one enzyme encoded from this gene family (SmAP), named SmCD1, has been validated for the development of schistosomicidal drugs, since it has a key role in haemoglobin digestion by worms. OBJECTIVE: In this work, we integrated a structure-based virtual screening campaign, enzymatic assays and adult worms ex vivo experiments aiming to discover the first classes of SmCD1 inhibitors. METHODS: Initially, the 3D-structures of SmCD1, SmCD2 and SmCD3 were generated using homology modelling approach. Using these models, we prioritised 50 compounds from 20,000 compounds from ChemBridge database for further testing in adult worm aqueous extract (AWAE) and recombinant SmCD1 using enzymatic assays. FINDINGS: Seven compounds were confirmed as hits and among them, two compounds representing new chemical scaffolds, named 5 and 19, had IC(50) values against SmCD1 close to 100 μM while presenting binding efficiency indexes comparable to or even higher than pepstatin, a classical tight-binding peptide inhibitor of aspartyl proteases. Upon activity comparison against mammalian enzymes, compound 50 was selective and the most potent against the AWAE aspartic protease activity (IC(50) = 77.7 μM). Combination of computational and experimental results indicate that compound 50 is a selective inhibitor of SmCD2. Compounds 5, 19 and 50 tested at low concentrations (10 uM) were neither cytotoxic against WSS-1 cells (48 h) nor could kill adult worms ex-vivo, although compounds 5 and 50 presented a slight decrease on female worms motility on late incubations times (48 or 72 h). MAIN CONCLUSION: Overall, the inhibitors identified in this work represent promising hits for further hit-to-lead optimisation. Instituto Oswaldo Cruz, Ministério da Saúde 2023-09-01 /pmc/articles/PMC10481938/ /pubmed/37672425 http://dx.doi.org/10.1590/0074-02760230031 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Research Article
Gomes, Bárbara Figueira
Senger, Mario Roberto
Moreira-Filho, José Teófilo
de Vasconcellos, Fabio Jorge
Dantas, Rafael Ferreira
Owens, Raymond
Andrade, Carolina Horta
Neves, Bruno Junior
Silva-Junior, Floriano Paes
Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening
title Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening
title_full Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening
title_fullStr Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening
title_full_unstemmed Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening
title_short Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening
title_sort discovery of new schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481938/
https://www.ncbi.nlm.nih.gov/pubmed/37672425
http://dx.doi.org/10.1590/0074-02760230031
work_keys_str_mv AT gomesbarbarafigueira discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening
AT sengermarioroberto discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening
AT moreirafilhojoseteofilo discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening
AT devasconcellosfabiojorge discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening
AT dantasrafaelferreira discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening
AT owensraymond discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening
AT andradecarolinahorta discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening
AT nevesbrunojunior discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening
AT silvajuniorflorianopaes discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening